



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission	Application Number	09/806,657
	Filing Date	October 4, 1999
	First Named Inventor	Peter Bernstein
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	ASZN0017-100 (Z70402-1P US)


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Table A - Statement Under 37 CFR 3.73(b) - executed Assignment - Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Cozen O'Connor, P.C.		
Signature			
Printed Name	Paul K. Legaard		
Date	10 MAY 2005	Reg. No.	38,534

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Paul K. Legaard	Date	10 MAY 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 18 2005
TECH CENTER 1600/2900 #11
HKO
5-26-05

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby revoke all previous powers of attorney or authorizations of agent given in the applications identified in Table A attached hereto, and appoint

☒ Practitioners at Customer Number: **52286**

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for all applications identified in Table

A to:

☒ Practitioners at Customer Number: **52286**

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Respectfully submitted,
ASTRAZENECA AB

Date: 13 April 2005

By: Christer Wahlström

Name: Christer Wahlström

Title: Director Patent Operations



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 18 2005
TECH CENTER 1600/2900

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, **AstraZeneca AB**, a corporation, states that it is:

☒ the assignee of the entire right, title, and interest of the applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is **100%** in the patent applications identified in Table A by virtue of:

☒ a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

ASTRAZENECA AB

Date: 13 April 2005

By: Christer Wahlström

Name: Christer Wahlström

Title: Director Patent Operations

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

BERNSTEIN, Peter, Robert; DEDINAS, Robert, Frank; OHNMACHT, Cyrus, John; RUSSELL, Keith; SHERWOOD, Scott, Alan; of 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; and 135 D Highland Boulevard, New Castle, DE 19720, US, respectively, citizens of the United States, the United States, the United States, the United Kingdom and the United States, respectively.

hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS

and which is found in

- (a) ___ U.S. patent application executed on even date herewith;
- (b) ___ U.S. patent application executed on _____;
- (c) ___ U.S. application serial no. filed on _____;
- (d) X International application no. PCT/GB99/03274 filed on 4 October 1999

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;

ASSIGNOR(S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this

29 day of March, 2001

Peter Robert Bernstein
Peter Robert Bernstein

WITNESS: Frances Koubals

DATE: 29 MARCH 2001

WITNESS: Anzla Khatky

DATE: 29 March 2001



Additional page(s) are attached hereto.

29 day of March, 2001

Robert Frank Dedinas
Robert Frank Dedinas

WITNESS: Francis Tomkins
DATE: 29 MARCH 2001

WITNESS: Angela Kiatky
DATE: 29 March 2001

29 day of March, 2001

Cyrus John Ohnmacht
Cyrus John Ohnmacht

WITNESS: Francis Tomkins
DATE: 29 March 2001

WITNESS: Angela Kiatky
DATE: 29 March 2001

29 day of March, 2001

Keith Russell
Keith Russell

WITNESS: Francis Tomkins
DATE: 29 MARCH 2001

WITNESS: Angela Kiatky
DATE: 29 March 2001

____ day of _____, 2001

Scott Alan Sherwood

WITNESS: _____

DATE: _____

WITNESS: _____

DATE: _____

☐ Additional page(s) are attached hereto.

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

BERNSTEIN, Peter, Robert; DEDINAS, Robert, Frank; OHNMACHT, Cyrus, John; RUSSELL, Keith; SHERWOOD, Scott, Alan; of 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; and 135 D Highland Boulevard, New Castle, DE 19720, US, respectively, citizens of the United States, the United States, the United States, the United Kingdom and the United States, respectively.

hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS

and which is found in

- (a) ___ U.S. patent application executed on even date herewith;
- (b) ___ U.S. patent application executed on _____;
- (c) ___ U.S. application serial no. filed on _____
- (d) ☒ International application no. PCT/GB99/03274 filed on 4 October 1999

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;

ASSIGNOR(S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this

_____ day of _____, 2001

Peter Robert Bernstein

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

☒ Additional page(s) are attached hereto.

____ day of _____, 2001

Robert Frank Dedinas

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

____ day of _____, 2001

Cyrus John Ohnmacht

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

____ day of _____, 2001

Keith Russell

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

☒ Additional page(s) are attached hereto.

27th day of March, 2001

Scott Alan Sherwood
Scott Alan Sherwood

WITNESS: Thomas S. Senkevich
DATE: MARCH 27, 2001

WITNESS: Joselyn Senkevich
DATE: March 27, 2001




TABLE A

Our Ref. AstraZeneca Ref.	Serial No. Filing Date	First Inventor	Examiner Art Unit	Title
ASZN0005-100 100368-1P US	10/477,851 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-101 100369-1P US	10/477,854 5/16/02	Brown	Celia C. Chang 1625	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-102 100372-1P US	10/477,853 5/16/02	Brown	Rita J. Desai 1625	4-(Phenyl-(piperidin-4-yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-103 100373-1P US	10/477,633 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0005-104 100375-1P US	10/477,636 5/16/02	Brown	Rita J. Desai 1625	4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders
ASZN0006-100 100514-1P US	10/497,565 12/11/02	Leung	Not Yet Assigned	Benzodiazepine Derivatives, Preparation Thereof And Use Thereof
ASZN0007-100 100590-1P US	10/498,864 12/17/02	Cheng	Not Yet Assigned	Therapeutic Heterocycles
ASZN0008-100 100100-1P US	10/333,669 1/21/03	Patel	Raymond K. Covington 1625	Process For Asymmetric Synthesis Of Substituted 1,4-Dihydropyridines
ASZN0009-100 100102-1P US	10/333,654 9/5/03	Patel	Alton N. Pryor 1616	Process For Synthesis Of Alpha,Beta-unsaturated Ketones

ASZN0010-100 100541-1P US	10/494,387 4/30/04	Bialecki	Raymond J. Henley III 1614	Method For The Treatment Of Overactive Bladder
ASZN0010-101 100542-1P US	10/494,195 11/1/02	Bialecki	Not Yet Assigned	Compounds And Method For The Treatment Of Overactive Bladder
ASZN0011-100 100570-1P US	10/502,191 1/23/03	Jones	D. Margaret M. Seaman 1625	Method
ASZN0012-100 100186-1P US	10/415,853 11/3/03	Chapdelaine	Not Yet Assigned 1614	N-type Calcium Channel Antagonists For The Treatment Of Pain
ASZN0012-101 100463-1P US	10/488,066 8/9/04	D'Amico	D. Margaret M. Seaman 1625	N-type Calcium Channel Antagonists For The Treatment Of Pain
ASZN0012-102 100464-1P US	10/488,025 8/23/02	D'Amico	Not Yet Assigned	N-type Calcium Channel Antagonists For The Treatment Of Pain
ASZN0013-100 Z70624-1P US	10/168,758 11/25/02	Chapdelaine	Maury A. Audet 1654	Cd45 Inhibitors
ASZN0013-101 Z70626-1P US	10/168,477 11/25/02	Chapdelaine	Kevin Weddington 1614	Cd45 Inhibitors
ASZN0014-100 100121-1P US	10/333,658 7/31/01	Bernstein	Shailendra Kumar 1621	N-(2-phenyl-3-aminopropyl)naphthamides
ASZN0015-100 100174-1P US	10/381,755 3/26/03	Bernstein	Bruck Kifle 1624	Cyclized Benzamide Neurokinin Antagonists For Use Therapy
ASZN0016-100 100237-1P US	10/450,284 12/20/01	Shenvi	Celia C. Chang 1625	Compounds

ASZN0017-100 Z70402-1P US	09/806,657 10/4/99	Bernstein	Not Yet Assigned	Naphthalenecarboxamides As Tachykinin Receptor Antagonists
ASZN0018-100 100003-2P US	11/042,752 1/24/05	Albert	Not Yet Assigned	Neurokinin Antagonists For Use As Medicaments
ASZN0019-100 100848-1P US	10/528,640 10/2/03	Becker	Not Yet Assigned	Novel Lactams And Uses Thereof